Impact News +++ Navan (NAVN) Sued Over IPO Disclosures; Investors Face April 24 Deadline - Hagens Berman (PR Newswire) +++ NAVAN Aktie -4,27%

UNIQURE Aktie

>UNIQURE Aktienkurs

14.46 EUR +2.3% (TradegateBSX)

Ask: 14.735 EUR / 120 Stück

Bid: 14.38 EUR / 120 Stück

Tagesumsatz: 4373 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

UNIQURE Aktie über LYNX handeln

Intraday

1 Jahr

>UNIQURE Performance

1 Woche: +2,1%

1 Monat: +10,0%

3 Monate: -30,5%

6 Monate: -69,4%

1 Jahr: +48,8%

laufendes Jahr: -30,5%

>UNIQURE Aktie

Name:

UNIQURE N.V. EO -,05

Land:

Niederlande

Sektor:

Gesundheit

ISIN/ Wkn:

NL0010696654 / A1XDTV

Symbol/ Ticker:

UQ1 (Frankfurt) / QURE (NASDAQ)

Kürzel:

FRA:UQ1, ETR:UQ1, UQ1:GR, NASDAQ:QURE

Index:

Webseite:

https://www.uniqure.com/

Profil:

uniQure N.V. is a biopharmaceutical company based in the Netherlands, specializing in the discovery, development, and commercialization of innovative gene therapies for patients with severe genetic and neurological disorders. It leverages a proprieta..
>Volltext..

Marktkapitalisierung:

784.58 Mio. EUR

Unternehmenswert:

712.06 Mio. EUR

Umsatz:

13.92 Mio. EUR

EBITDA:

-154.56 Mio. EUR

Nettogewinn:

-172.04 Mio. EUR

Gewinn je Aktie:

-3.01 EUR

Schulden:

463.95 Mio. EUR

Liquide Mittel:

69.38 Mio. EUR

Operativer Cashflow:

-158.69 Mio. EUR

Bargeldquote:

9.89

Umsatzwachstum:

-47.68%

Gewinnwachstum:

26.79%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

4 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 848.266 USD.

Suchwörter:

UNIQURE

Letzte Datenerhebung:

01.04.26

>UNIQURE Kennzahlen

Aktien/ Unternehmen:

Aktien: 61.6 Mio. St.

Frei handelbar: 90.03%

Leerverk. Aktien: 20.34%

Rückkaufquote: -44.54%

Mitarbeiter: 221

Umsatz/Mitarb.: 0.06 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 134.71%

Bewertung:

KGV: -

KGV lG: -

KUV: 60.15

KBV: 5.02

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -2.16%

Gewinnmarge: -1236%

Operative Marge: -1202.09%

Managementeffizenz:

Gesamtkaprendite: -28.81%

Eigenkaprendite: -207.1%

>UNIQURE Peer Group

Gesundheit, Neurologische- & psychische Behandlung/ Medizin, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>UNIQURE Chart & Kurs - NASDAQ

>UNIQURE News

02.04.26 - 01:12	QURE Deadline: QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, April 1, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead......

01.04.26 - 20:27	QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism; April 13 Deadline Nears (PR Newswire)
	SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials. This investigation follows the filing of a......

31.03.26 - 15:03	QURE Shareholder Alert: uniQure N.V. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm (PR Newswire)
	NEW YORK, March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (NASDAQ: QURE). Shareholders who purchased shares of QURE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.......

30.03.26 - 21:54	QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data (PR Newswire)
	Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending Suit SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug......

30.03.26 - 19:01	uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline (PR Newswire)
	Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V. Investor Summary Who: uniQure N.V. (NASDAQ: QURE) What: Securities fraud class action lawsuit filed Class Period: September 24, 2025, and October 31, 2025 Deadline to Seek Lead......

30.03.26 - 10:09	uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE (PR Newswire)
	LOS ANGELES, March 30, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by......

30.03.26 - 10:03	QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, March 30, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act......

29.03.26 - 14:21	QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in uniQure between September 24, 2025 and October 31, 2025 and would like to......

28.03.26 - 03:36	uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC (PR Newswire)
	NEW YORK and NEW ORLEANS, March 27, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 13, 2026 to file lead plaintiff applications in a......

27.03.26 - 20:33	QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, March 27, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff......

26.03.26 - 21:39	QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data (PR Newswire)
	Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending Suit SAN FRANCISCO, March 26, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug......

25.03.26 - 00:21	uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed; April 13, 2026, Lead Plaintiff Deadline (PR Newswire)
	Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V. Investor Summary Who: uniQure N.V. (NASDAQ: QURE) What: Securities fraud class action lawsuit filed Class Period: September 24, 2025, and October 31, 2025 Deadline to Seek Lead......

24.03.26 - 17:33	QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data (PR Newswire)
	Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending Suit SAN FRANCISCO, March 24, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug......

24.03.26 - 01:57	QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, March 23, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff......

22.03.26 - 13:45	QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in UniQure between September 24, 2025 and October 31, 2025 and would like to......

21.03.26 - 03:33	uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE (PR Newswire)
	NEW ORLEANS, March 20, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V. (NasdaqGS: QURE) ("uniQure" or the......

20.03.26 - 21:33	QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data (PR Newswire)
	Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending Suit SAN FRANCISCO, March 20, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug......

20.03.26 - 09:27	QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, March 20, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act......

20.03.26 - 08:24	uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE (PR Newswire)
	LOS ANGELES, March 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by......

19.03.26 - 22:42	Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline (PR Newswire)
	Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V. Investor Summary Who: uniQure N.V. (NASDAQ: QURE) What: Securities fraud class action lawsuit filed Class Period: September 24, 2025, and October 31, 2025 Deadline to Seek Lead......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Don′t marry, be happy. - Hera Lind

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram